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Introduction: Serum levels of CA125 are often high in advanced heart failure (AHF) patients.
Aim: To determine the predictive value of CA125 in forecasting the occurrence of death or cardiac transplantation in an AHF population.
Methods: 88 AHF patients referred for heart transplantation were divided into 2 groups based on CA125 levels: normal (CA125b38 U/mL)
and elevated (≥38 U/mL). Events (death or heart transplant) were monitored over a period of 13±7 months after CA125 determination.
Results: Patients with elevated CA125 (n=65) had significantly lower blood pressure, body mass index, serum sodium and peak exercise
oxygen consumption, while B-type natriuretic peptide levels were significantly higher. The combined primary endpoint (death or heart
transplant) rate was 39.4% and 62.3% in normal and elevated CA125 groups, respectively (p=0.029). Multivariate regression analysis
showed that CA125 and sodium levels were the only independent predictors of the combined endpoint.
Conclusion: In AHF patients, plasma CA125 was an effective prognostic marker. Its determination may contribute to better risk stratification
in this population.
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Clinical characteristics of the study population of advanced heart failure
patients (n=88)
Age (years) 53.5±13.8
Men/women 62 (70%)/26 (30%)
Body mass index (kg/m2) 24.0±5.0
LVEF (%) 24.5±11.2
NYHA functional class (%)
III 58.1
IV 41.9
Aetiology (%)
Dilated cardiomyopathy 49
Coronary artery disease 40
Hypertensive heart disease 101. Introduction
Advanced heart failure (AHF) is associated with high
morbidity and mortality rates [1–3], unless cardiac trans-
plantation is performed. Risk stratification of AHF patients is
a critical component of the transplant candidate selection
process; therefore, search for new prognostic markers in
AHF has recently been intensified.
Carbohydrate antigen 125 (CA125) is a tumour marker
classically associated with ovarian cancer [4]; recently several
studies reported increased serum CA125 levels in HF patients
[5–15].⁎ Corresponding author. Tel.: +351966556027; fax: +351239084893.
E-mail address: silvia.reis.monteiro@gmail.com (S. Monteiro).
Other 1
Data are presented as the mean value±SD, number or percentage of patients.
LVEF — left ventricular ejection fraction; NYHA — New York Heart
Association.
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Table 2
Clinical, laboratory and echocardiographic parameters of advanced heart
failure patients, classified according to CA125 levels
CA125b38 U/mL CA125≥38 U/mL p
Heart rate (bpm) 73.8±11.5 83.1±15.3 0.015
SBP (mmHg) 109.8±17.7 97.0±14.6 0.006
DBP (mmHg) 66.1±13.8 56.7±10.3 0.01
Body mass index (kg/m2) 24.8±6.5 23.4±3.2 0.04
Serum Sodium (mmol/L) 135.9±4.5 133.9±4.1 0.04
Serum creatinine (mg/dL) 1.4±0.5 1.7±1.7 0.80
BNP (pg/mL) 593.4±554.9 2180.1±1468.7 b0.001
LVEF (%) 24.7±11.5 24.3±11.1 0.92
Peak VO2 (mL/kg/min) 16.0±5.1 13.8±3.4 0.049
SBP— systolic blood pressure; DBP— diastolic blood pressure; BNP— B
type natriuretic peptide; LVEF — left ventricular ejection fraction; Peak
VO2 — peak exercise oxygen consumption.
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ARTICLE IN PRESSHowever, it is still a matter of debate if CA125 is a potential
prognostic marker for AHF and also if it is useful for
evaluating and managing pre-transplant patients.
The aim of the present studywas to determine the predictive
value of plasma CA125 in forecasting the occurrence of death
or cardiac transplantation in an AHF patient population.
1.1. Patients and methods
This study included 88 consecutive AHF patients referred
for heart transplantation (62 male, mean age 53.5±13.8
years) — Table 1.
CA125 assayswere performed during clinic visits or during
hospitalization for HF, after clinical stabilization (7±3 days).
Serum levels of CA125weremeasured by chemiluminescence
(BRAHMSCA125 II KRYPTOR), with an upper normal limitFig. 1. Kaplan–Meier cumulative event-free surviva
Please cite this article as: Monteiro S, et al., Prognostic value of CA125 i
ijcard.2008.11.023of 38 U/mL. Population was divided into two groups
according to CA125 levels: normal (CA125b38 U/mL) and
elevated (≥38 U/mL).
Patients were followed for a mean period of 13±7 months
after CA125 assessment; the study primary endpoint was
death or heart transplant.
1.2. Statistical analysis
Data are presented as the mean value±SD. Analysis of
groups differences was performed using the Mann–Whitney
U test for continuous variables and χ2 test for categorical
variables. A p valueb0.05 was considered statistically sig-
nificant. Survival curves were constructed by the Kaplan–
Meier method and were compared using the log-rank test.
Multivariate regression analysis was then performed to
determine the independent predictors of the primary endpoint.
2. Results
Twenty-three patients had normal CA125 (15.3±6.1U/mL),
while 65 had elevated levels (215.6±260.2 U/mL). Groups
were similar regarding demographic characteristics, HF
aetiology and medication.
Compared to the normal group, patients with elevated
CA125 had significantly lower systolic and diastolic blood
pressure, body mass index, serum sodium and peak oxygen
consumption in the cardio–respiratory stress test. B-type
natriuretic peptide (BNP) levels were also significantly
higher in this group (Table 2).
In elevated CA125 group, 38% of patients had pleural
effusion versus none in normal CA125 group (p=0.014).l curves separated according to CA125 levels.
n advanced heart failure patients, Int J Cardiol (2009), doi:10.1016/j.
Table 3
Multiple regression analysis
Variables Beta p-value OR
CA125≥38 U/mL 1.152 0.032 3.163 (1.107–9.036)
NA≤132.5 mmol/L 1.339 0.041 3.817 (1.056–13.799)
c-statistic 0.728.
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ARTICLE IN PRESSEvent rate was significantly lower in patients with normal
CA125 levels: 2 versus 15 died, 11 versus 19were transplanted
and 13 versus 27 were readmitted for worsening HF. The
combined primary endpoint (death or heart transplant) ratewas
39.4% in patients with normal CA125 values and 62.3% in the
elevated CA125 group (p=0.029)— Fig. 1.
Multivariate regression analysis showed that CA125 and
sodium levels were the only independent predictors of the
combined endpoint (Table 3).
3. Discussion
Numerous studies showed increased CA125 levels in
CHF patients and a relationship between these values and HF
severity [5–15]. In the present study, we investigated the
prognostic value of CA125 levels in an AHF population.
According to our results, serum CA125 was elevated in
most AHF patients and its levels were significantly related to
blood pressure, bodymass index, serum sodium, peak exercise
oxygen consumption and BNP levels (established markers of
severity and prognosis in HF).
We did not find significant differences in LVEF between
patients with normal and elevated CA125, probably because
our population included mainly severe AHF patients with
low LVEF (24.5±11.2%) and LVEF is not a good marker to
stratify AHF patients [1].
Our data clearly demonstrated that CA125 is a marker
of adverse outcome in AHF patients, associated with in-
creased mortality, transplant and hospital readmission rates.
Multivariate analysis identified CA125 as an indepen-
dent predictor for the combined endpoint death or heart
transplant.
In several reports high CA125 was associated with serosal
effusions, suggesting that the presence of serosal fluids may
stimulate its release [8–10].
However, other investigators showed increased CA125
levels in HF patients without serosal effusion, indicating that an
acute congestion may not be the sole cause of CA125 secretion
[6,7].
The majority of our patients with high CA125 did not have
pleural effusion, either because they were clinically stable or
because many AHF patients do not have serosal effusions.
Recently, Kosar [16] demonstrated that high CA125
levels in HF patients were correlated with inflammatory cyto-
kines levels, suggesting a relationship between CA125 and
cytokines.
As in our study CA125 was measured during routine
clinic visits or in hospitalized patients (but after clinicalPlease cite this article as: Monteiro S, et al., Prognostic value of CA125 i
ijcard.2008.11.023stabilization), our results support the hypothesis that CA125
is an effective marker of AHF severity and prognosis, even in
compensated phases of the disease.
4. Conclusion
In AHF patients, CA125 is an independent predictor
of worse prognosis, associated with a higher event rate
and increased mortality. Even in stable patients CA125 is a
useful marker of AHF severity and prognosis, which can be
used to improve risk stratification and guide therapeutic
decisions.
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